Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Naveen S. Vasudev, PhD, MBChB, on Ipilimumab Plus Nivolumab for RCC: Duration of First-Line Treatment

Posted: Tuesday, September 28, 2021

Naveen S. Vasudev, PhD, MBChB, of the University of Leeds, discusses the possible impact of the PRISM trial findings on how often ipilimumab plus nivolumab should be given to patients with advanced renal cell carcinoma who are undergoing first-line treatment. He describes what may be next in terms of devising strategies that might improve patients’ quality of life in this setting.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.